Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Debt to Equity (2024)

Crescent Biopharma has reported Debt to Equity over the past 1 years, most recently at -$2.42 for Q4 2024.

  • Quarterly Debt to Equity changed N/A to -$2.42 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$2.42 through Dec 2024, changed N/A year-over-year, with the annual reading at -$2.42 for FY2024, N/A changed from the prior year.
  • Debt to Equity was -$2.42 for Q4 2024 at Crescent Biopharma.
  • Over five years, Debt to Equity peaked at -$2.42 in Q4 2024 and troughed at -$2.42 in Q4 2024.